VANDA PHARMACEUTICALS INC's ticker is VNDA and the CUSIP is 921659108. A total of 165 filers reported holding VANDA PHARMACEUTICALS INC in Q3 2018. The put-call ratio across all filers is 0.33 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $8,706,161 | +127.9% | 2,015,315 | +247.6% | 0.00% | +100.0% |
Q2 2023 | $3,820,711 | +31840.4% | 579,774 | -67.1% | 0.00% | -71.4% |
Q1 2023 | $11,962 | -9.3% | 1,761,728 | -1.2% | 0.01% | 0.0% |
Q4 2022 | $13,182 | -99.1% | 1,783,745 | +1089.5% | 0.01% | +600.0% |
Q3 2022 | $1,482,000 | -88.6% | 149,957 | -87.4% | 0.00% | -87.5% |
Q2 2022 | $12,975,000 | +37.6% | 1,190,410 | +42.7% | 0.01% | +60.0% |
Q1 2022 | $9,432,000 | +36.7% | 833,992 | +89.7% | 0.01% | +25.0% |
Q4 2021 | $6,898,000 | -33.7% | 439,674 | -27.5% | 0.00% | -33.3% |
Q3 2021 | $10,400,000 | +89.2% | 606,744 | +137.4% | 0.01% | +100.0% |
Q2 2021 | $5,498,000 | -48.9% | 255,607 | -64.3% | 0.00% | -62.5% |
Q1 2021 | $10,765,000 | +27.3% | 716,715 | +11.3% | 0.01% | +33.3% |
Q4 2020 | $8,458,000 | +422.1% | 643,710 | +283.9% | 0.01% | +200.0% |
Q3 2020 | $1,620,000 | -44.2% | 167,657 | -40.2% | 0.00% | -71.4% |
Q1 2020 | $2,903,000 | +1201.8% | 280,178 | +1958.2% | 0.01% | – |
Q4 2019 | $223,000 | -96.4% | 13,613 | -97.1% | 0.00% | -100.0% |
Q3 2019 | $6,135,000 | -16.6% | 461,975 | -11.6% | 0.01% | -9.1% |
Q2 2019 | $7,360,000 | -39.2% | 522,325 | -20.6% | 0.01% | -38.9% |
Q1 2019 | $12,108,000 | -29.8% | 658,022 | -0.3% | 0.02% | -33.3% |
Q4 2018 | $17,240,000 | +136.5% | 659,764 | +107.7% | 0.03% | +200.0% |
Q3 2018 | $7,289,000 | -2.0% | 317,591 | -18.7% | 0.01% | -10.0% |
Q2 2018 | $7,437,000 | -55.7% | 390,402 | -60.8% | 0.01% | -54.5% |
Q1 2018 | $16,787,000 | -2.1% | 996,275 | -11.6% | 0.02% | -8.3% |
Q4 2017 | $17,139,000 | -33.5% | 1,127,565 | -21.7% | 0.02% | -38.5% |
Q3 2017 | $25,790,000 | +264.2% | 1,440,761 | +231.6% | 0.04% | +200.0% |
Q2 2017 | $7,082,000 | -11.2% | 434,479 | -23.7% | 0.01% | -13.3% |
Q1 2017 | $7,971,000 | -51.1% | 569,343 | -44.2% | 0.02% | -55.9% |
Q4 2016 | $16,288,000 | -41.8% | 1,021,171 | -39.3% | 0.03% | -27.7% |
Q3 2016 | $27,983,000 | +472.4% | 1,681,681 | +284.9% | 0.05% | +327.3% |
Q2 2016 | $4,889,000 | -73.0% | 436,911 | -79.9% | 0.01% | -75.6% |
Q1 2016 | $18,131,000 | +26.8% | 2,168,736 | +41.2% | 0.04% | +50.0% |
Q4 2015 | $14,298,000 | -29.4% | 1,535,770 | -14.5% | 0.03% | -23.1% |
Q3 2015 | $20,253,000 | +47.3% | 1,795,468 | +65.7% | 0.04% | +50.0% |
Q2 2015 | $13,753,000 | -7.5% | 1,083,759 | -32.2% | 0.03% | -7.1% |
Q1 2015 | $14,872,000 | +27.8% | 1,599,162 | +96.8% | 0.03% | +12.0% |
Q4 2014 | $11,639,000 | +81.0% | 812,770 | +31.2% | 0.02% | +56.2% |
Q3 2014 | $6,431,000 | +52.8% | 619,579 | +138.1% | 0.02% | +33.3% |
Q2 2014 | $4,210,000 | +29.5% | 260,207 | +30.1% | 0.01% | +33.3% |
Q1 2014 | $3,250,000 | -74.2% | 200,000 | -80.3% | 0.01% | -76.9% |
Q4 2013 | $12,590,000 | -33.1% | 1,014,430 | -41.0% | 0.04% | -36.1% |
Q3 2013 | $18,832,000 | +195.2% | 1,719,820 | +117.8% | 0.06% | +221.1% |
Q2 2013 | $6,380,000 | – | 789,698 | – | 0.02% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
ARMISTICE CAPITAL, LLC | 1,532,000 | $27,423,000 | 3.23% |
Stonepine Capital Management, LLC | 300,000 | $5,370,000 | 3.16% |
Palo Alto Investors LP | 4,155,670 | $74,386,000 | 3.13% |
GREAT POINT PARTNERS LLC | 497,531 | $8,906,000 | 1.73% |
Avoro Capital Advisors LLC | 988,270 | $17,690,000 | 1.37% |
UNIVERSITY OF NOTRE DAME DU LAC | 157,781 | $2,824,000 | 0.79% |
Birchview Capital, LP | 68,000 | $1,217,000 | 0.63% |
Cheyne Capital Management (UK) LLP | 74,000 | $1,323,000 | 0.48% |
BOGLE INVESTMENT MANAGEMENT L P /DE/ | 352,604 | $6,311,000 | 0.43% |
361 CAPITAL LLC | 119,554 | $2,140,000 | 0.41% |